These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12856128)

  • 1. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population.
    Lopes C; Dina C; Durand E; Froguel P
    Diabetologia; 2003 Sep; 46(9):1284-90. PubMed ID: 12856128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children.
    Berberoğlu M; Evliyaoğlu O; Adiyaman P; Ocal G; Ulukol B; Simşek F; Siklar Z; Törel A; Ozel D; Akar N
    J Pediatr Endocrinol Metab; 2006 May; 19(5):741-8. PubMed ID: 16789641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
    Festa A; D'Agostino R; Rich SS; Jenny NS; Tracy RP; Haffner SM
    Circulation; 2003 May; 107(19):2422-7. PubMed ID: 12719278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Val17Ile single nucleotide polymorphisms similarly as Ala15Thr could be related to the lower secretory dynamics of PAI-1 secretion: theoretical evidence.
    Jankun J; Skrzypczak-Jankun E
    Curr Mol Med; 2011 Aug; 11(6):512-6. PubMed ID: 21663586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.
    Zietz B; Buechler C; Drobnik W; Herfarth H; Schölmerich J; Schäffler A
    Endocr Res; 2004 Aug; 30(3):443-53. PubMed ID: 15554360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity.
    Naran NH; Chetty N; Crowther NJ
    Atherosclerosis; 2008 Jan; 196(1):155-163. PubMed ID: 17467713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia.
    Yende S; Angus DC; Ding J; Newman AB; Kellum JA; Li R; Ferrell RE; Zmuda J; Kritchevsky SB; Harris TB; Garcia M; Yaffe K; Wunderink RG;
    Am J Respir Crit Care Med; 2007 Dec; 176(11):1129-37. PubMed ID: 17761618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of metabolic syndrome and its components with -844 G/A and HindIII C/G PAI-1 gene polymorphisms in Mexican children.
    De la Cruz-Mosso U; Muñoz-Valle JF; Salgado-Goytia L; García-Carreón A; Illades-Aguiar B; Castañeda-Saucedo E; Parra-Rojas I
    BMC Pediatr; 2012 Mar; 12():41. PubMed ID: 22459021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.
    Lin S; Huiya Z; Bo L; Wei W; Yongmei G
    Endocrine; 2009 Dec; 36(3):503-9. PubMed ID: 19856137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity.
    Hoffstedt J; Andersson IL; Persson L; Isaksson B; Arner P
    Diabetologia; 2002 Apr; 45(4):584-7. PubMed ID: 12032637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association analysis of the plasminogen activator inhibitor-1 4G/5G polymorphism in Hispanics and African Americans: the IRAS family study.
    Bensen JT; Hsu FC; Brown WM; Sutton BS; Norris JM; Tracy RP; Jenny NS; Saad MF; Haffner S; Bowden DW; Langefeld CD
    Hum Hered; 2004; 57(3):128-37. PubMed ID: 15297806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
    Espino A; Villagrán A; Vollrath V; Hanckes P; Salas R; Farah A; Solís N; Pizarro M; Escalona A; Boza C; Pérez G; Carrasco G; Padilla O; Miquel JF; Nervi F; Chavez-Tapia NC; Arab JP; Alvarez-Lobos M; Arrese M; Riquelme A
    Ann Hepatol; 2011; 10(4):493-501. PubMed ID: 21911891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of plasminogen activator inhibitor 1 gene 4G/5G polymorphisms to hypertension in Korean women.
    Kim KN; Kim KM; Kim BT; Joo NS; Cho DY; Lee DJ
    Chin Med J (Engl); 2012 Apr; 125(7):1249-53. PubMed ID: 22613596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
    Sartori MT; Vettor R; De Pergola G; De Mitrio V; Saggiorato G; Della Mea P; Patrassi GM; Lombardi AM; Fabris R; Girolami A
    Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: a case-control study in adults.
    Ringelstein M; Jung A; Berger K; Stoll M; Madlener K; Klötzsch C; Schlachetzki F; Stolz E
    J Neurol; 2012 Nov; 259(11):2287-92. PubMed ID: 22527222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children.
    Haralambous E; Hibberd ML; Hermans PW; Ninis N; Nadel S; Levin M
    Crit Care Med; 2003 Dec; 31(12):2788-93. PubMed ID: 14668616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of the type 1 plasminogen activator inhibitor 4G/5G gene polymorphism to impaired fibrinolysis in vital exhaustion.
    von Känel R; Maly FE; Frey K; Fischer JE
    Ital Heart J; 2003 Nov; 4(11):791-6. PubMed ID: 14699709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of plasminogen activator inhibitor-1 gene 4G/5G polymorphism on glucose and lipid metabolisms in Turkish obese children.
    Kinik ST; Ataç FB; Verdi H; Cetintaş S; Sahin FI; Ozbek N
    Clin Endocrinol (Oxf); 2005 May; 62(5):607-10. PubMed ID: 15853833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 (PAI-1) antigen plasma levels in subjects attending a metabolic ward: relation to polymorphisms of PAI-1 and angiontensin converting enzyme (ACE) genes.
    Margaglione M; Grandone E; Vecchione G; Cappucci G; Giuliani N; Colaizzo D; Celentano E; Panico S; Di Minno G
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2082-7. PubMed ID: 9351375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.